Paper. Signor A, Comai S, Pasut G et al.. British Journal of Clinical Pharmacology, 21 Sep 2026.
Tags: Human, Psilocybin.
phase 1 SAD of a modified-release psilocybin (REL-P11) at 0.5-2 mg aimed at sub-perceptual metabolic dosing, in normal-weight and obese adults
Read the original